Endo International PLC (ENDP) Short Interest Up 14.6% in August
Endo International PLC (NASDAQ:ENDP) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 13,712,139 shares, an increase of 14.6% from the August 15th total of 11,962,171 shares. Currently, 6.9% of the company’s stock are sold short. Based on an average daily trading volume, of 6,198,653 shares, the days-to-cover ratio is currently 2.2 days.
Endo International PLC (NASDAQ:ENDP) opened at 20.29 on Wednesday. The company’s market capitalization is $4.52 billion. The firm has a 50-day moving average price of $20.98 and a 200 day moving average price of $22.03. Endo International PLC has a 12 month low of $12.56 and a 12 month high of $77.21.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The company earned $921 million during the quarter, compared to the consensus estimate of $873.50 million. During the same period in the prior year, the company earned $1.08 earnings per share. The company’s revenue for the quarter was up 25.3% compared to the same quarter last year. Analysts expect that Endo International PLC will post $4.56 EPS for the current year.
Several large investors have recently made changes to their positions in the company. IFP Advisors Inc boosted its position in Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock valued at $226,000 after buying an additional 14,496 shares in the last quarter. Amalgamated Bank boosted its position in Endo International PLC by 240.1% in the second quarter. Amalgamated Bank now owns 28,122 shares of the company’s stock valued at $647,000 after buying an additional 19,853 shares in the last quarter. Panagora Asset Management Inc. boosted its position in Endo International PLC by 29.9% in the second quarter. Panagora Asset Management Inc. now owns 34,828 shares of the company’s stock valued at $543,000 after buying an additional 8,019 shares in the last quarter. HRS Investment Holdings LLC purchased a new position in Endo International PLC during the second quarter valued at $312,000. Finally, Schneider Capital Management Corp purchased a new position in Endo International PLC during the second quarter valued at $6,941,000. Institutional investors own 96.66% of the company’s stock.
Several equities research analysts have recently issued reports on ENDP shares. Goldman Sachs Group Inc. started coverage on Endo International PLC in a report on Monday, June 6th. They set a “neutral” rating and a $20.00 price target for the company. Mizuho upgraded Endo International PLC from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $13.00 to $16.00 in a report on Monday, June 13th. Deutsche Bank AG reiterated a “buy” rating and set a $31.00 price target on shares of Endo International PLC in a report on Wednesday, June 15th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Endo International PLC in a report on Saturday, June 25th. Finally, BMO Capital Markets started coverage on Endo International PLC in a report on Tuesday, June 28th. They set a “market perform” rating and a $21.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $39.32.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.